Rafraîchir
Imunexus - IPO for innovative biotechnology company
Vous souhaitez remporter un projet comme celui-ci ?
Ce client a reçu 240 designs de logo de la part de 47 designers. Il a choisi ce design de logo de logo_s comme design gagnant.
Inscrivez-vous Trouvez des Projets de Design
- Garanti
-
A$320
-
240 designs
-
47 designers
Brief de Design de Logo
We need a logo design for a new biotechnology company based in Melbourne, Australia. The company is called Imunexus, and is preparing for an initial public offering (IPO) on the Australian Stock Exchange (ASX). Imunexus offers a 'plug-and-play' technology platform for rapid development of 'biobetters', the rough equivalent of 'super-generic' drugs. Biobetters are improved biological drugs (e.g. antibodies) that are similar to the original antibody, but have substantive structural modifications that enhance the efficacy of the drug. Biobetters work much better than simple 'biosimilars' which are closer copies of the original drug, and do not work any better than the original drug. Please refer to the attached brief summary, in particular logo design concepts on page 3.
Mises à jour
Project Deadline Extended
Reason: Need to get consensus amongst Board.
Added Tuesday, June 2, 2015
Marché(s) Cible(s)
Biotechnology investors - high net worths, sophisticated, and retail
Secteur / Type d'entité
Biotechnology
Texte du logo
Imunexus
Styles de logo qui vous intéressent
Logo pictural
Un objet réel (texte facultatif)
Logo de figurine
Logo avec illustration ou personnage
Aspect
Chaque curseur illustre les caractéristiques de la marque client et le style que doit transmettre votre design de logo.
Élégant
Audacieux
Léger
Sérieux
Traditionnel
Moderne
Sympathique
Professionnelle
Féminin
Masculin
Coloré
Conservateur
Économique
Haut de gamme
Exigences
Doit avoir
- Please see page 3 of the attached brief. NOTE: We are not committed to the boomerang concept; it is one suggestion. Other concepts are welcome.
Bien d'avoir
- Please see page 3 of the attached brief. Innovation, next-generation, breakthrough, combination, nexus.
Ne doit pas comporter
- Please see page 3 of the attached brief
